94 related articles for article (PubMed ID: 30325731)
1. Pharmacogenetic testing by polymorphic markers G1846A (CYP2D6*4) and C100T (CYP2D6*10) of the CYP2D6 gene in coronary heart disease patients taking ββ-blockers in the Republic of Sakha (YAKUTIA).
Fedorinov DS; Mirzaev KB; Mustafina VR; Sychev DA; Maximova NR; Chertovskikh JV; Popova NV; Tarabukina SM; Rudykh ZA
Drug Metab Pers Ther; 2018 Dec; 33(4):195-200. PubMed ID: 30325731
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia).
Fedorinov DS; Mirzaev KB; Ivashchenko DV; Temirbulatov II; Sychev DA; Maksimova NR; Chertovskih JV; Popova NV; Tayurskaya KS; Rudykh ZA
Drug Metab Pers Ther; 2018 Jun; 33(2):91-98. PubMed ID: 29738309
[TBL] [Abstract][Full Text] [Related]
3. [CYP2D6 gene polymorphic markers role in determining the optimal treatment tactics for portal hypertension in patients with liver cirrhosis].
Sychev DA; Parusov AI; Loranskaya ID; Denisenko NP; Akmalova KA; Sozaeva ZA; Turkina OL; Zastrozhin MS
Ter Arkh; 2022 Feb; 94(2):200-208. PubMed ID: 36286743
[TBL] [Abstract][Full Text] [Related]
4. CYP2D6 (C2850T, G1846A, C100T) polymorphisms, haplotypes and MDR analysis in predicting coronary artery disease risk in north-west Indian population: A case-control study.
Bhat MA; Gandhi G
Gene; 2018 Jul; 663():17-24. PubMed ID: 29660517
[TBL] [Abstract][Full Text] [Related]
5. Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol.
Nozawa T; Taguchi M; Tahara K; Hashimoto Y; Igarashi N; Nonomura M; Kato B; Igawa A; Inoue H
J Cardiovasc Pharmacol; 2005 Nov; 46(5):713-20. PubMed ID: 16220080
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of the CYP2D6*10 (C100T), *4 (G1846A), and *14 (G1758A) alleles among Iranians of different ethnicities.
Bagheri A; Kamalidehghan B; Haghshenas M; Azadfar P; Akbari L; Sangtarash MH; Vejdandoust F; Ahmadipour F; Meng GY; Houshmand M
Drug Des Devel Ther; 2015; 9():2627-34. PubMed ID: 25999696
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction.
Goryachkina K; Burbello A; Boldueva S; Babak S; Bergman U; Bertilsson L
Eur J Clin Pharmacol; 2008 Dec; 64(12):1163-73. PubMed ID: 18648788
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety of bisoprolol in pregnant women with chronic arterial hypertension do not depend on genetic CYP2D6 polymorphism].
Brytkova IaV; Ignat'ev IV; Kazakov RE; Sokova EA; Striuk RI
Kardiologiia; 2009; 49(7-8):50-5. PubMed ID: 19656108
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
10. The frequencies of mutated alleles of CYP2D6 gene in a Turkish population.
Serin A; Canan H; Alper B; Gulmen M
Forensic Sci Int; 2012 Oct; 222(1-3):332-4. PubMed ID: 22910059
[TBL] [Abstract][Full Text] [Related]
11. [Patient age and CYP2D6*4/CYP2D6*3 genotype on maximal heart rate in patients after acute coronary syndrome treated with bisoprolol.].
Shumkov VA; Zagorodnikova KA; Boldueva SA; Murzina AA; Petrova VB
Adv Gerontol; 2021; 34(1):48-53. PubMed ID: 33993661
[TBL] [Abstract][Full Text] [Related]
12. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
Baudhuin LM; Miller WL; Train L; Bryant S; Hartman KA; Phelps M; Larock M; Jaffe AS
Am J Cardiol; 2010 Aug; 106(3):402-8. PubMed ID: 20643254
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms in ADRB1, ADRB2 and CYP2D6 genes and response to beta-blockers in patients with acute coronary syndrome.
Castaño-Amores C; Antúnez-Rodríguez A; Pozo-Agundo A; García-Rodríguez S; Martínez-González LJ; Dávila-Fajardo CL
Biomed Pharmacother; 2023 Dec; 169():115869. PubMed ID: 37952358
[TBL] [Abstract][Full Text] [Related]
14. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users.
Bijl MJ; Visser LE; van Schaik RH; Kors JA; Witteman JC; Hofman A; Vulto AG; van Gelder T; Stricker BH
Clin Pharmacol Ther; 2009 Jan; 85(1):45-50. PubMed ID: 18784654
[TBL] [Abstract][Full Text] [Related]
15. Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure.
Shihmanter R; Nulman I; Goland S; Caspi A; Bar-Haim A; Harary I; Berkovitch M; Arcavi L
J Clin Pharm Ther; 2014 Aug; 39(4):432-8. PubMed ID: 24673480
[TBL] [Abstract][Full Text] [Related]
16. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy.
Batty JA; Hall AS; White HL; Wikstrand J; de Boer RA; van Veldhuisen DJ; van der Harst P; Waagstein F; Hjalmarson Å; Kjekshus J; Balmforth AJ;
Clin Pharmacol Ther; 2014 Mar; 95(3):321-30. PubMed ID: 24193112
[TBL] [Abstract][Full Text] [Related]
17. 1846G>A polymorphism of CYP2D6 gene and extrapyramidal side effects during antipsychotic therapy among Russians and Tatars: a pilot study.
Sychev DA; Burashnikova IS; Kazakov RE
Drug Metab Pers Ther; 2016 Dec; 31(4):205-212. PubMed ID: 27875318
[TBL] [Abstract][Full Text] [Related]
18. Correlation of CYP2D6 allelic polymorphism to outcome of acute coronary syndrome in mid-Euphrates Iraqi patients on metoprolol therapy.
Swadi AA; Mohammad BI; Hadi NR; Al-Aubaidy HA
Gene; 2019 Jun; 703():112-119. PubMed ID: 30965129
[TBL] [Abstract][Full Text] [Related]
19. [Genetic polymorphisms in drug metabolizing enzymes--impact on treatment with beta-blockers].
Wuttke H; Rau T; Eschenhagen T
Dtsch Med Wochenschr; 2004 Apr; 129(15):831-5. PubMed ID: 15054690
[No Abstract] [Full Text] [Related]
20. Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to β-blocker therapy in hypertension.
Wu D; Li G; Deng M; Song W; Huang X; Guo X; Wu Z; Wu S; Xu J
J Int Med Res; 2015 Jun; 43(3):424-34. PubMed ID: 25823457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
